Ksilink https://ksilink.com/ from patient to drug Tue, 02 Sep 2025 19:41:42 +0000 en-US hourly 1 https://ksilink.com/wp-content/uploads/2020/09/cropped-favicon-ksilink-32x32.png Ksilink https://ksilink.com/ 32 32 Meet us at Conferences and Partnerings https://ksilink.com/conferences-and-partnerings-2025/ Tue, 02 Sep 2025 14:25:04 +0000 https://ksilink.com/?p=7362 We’re excited to be present at a series of dynamic conferences, partnering events, and investor meetings throughout the rest of the year. If you’re attending too, don’t hesitate to reach out in advance – we’d love to meet in person, hear about your plans and needs, and share how we’re working to transform drug discovery. […]

L’article Meet us at Conferences and Partnerings est apparu en premier sur Ksilink.

]]> We’re excited to be present at a series of dynamic conferences, partnering events, and investor meetings throughout the rest of the year. If you’re attending too, don’t hesitate to reach out in advance – we’d love to meet in person, hear about your plans and needs, and share how we’re working to transform drug discovery.

Here’s where you can find us:

Symposium 2050, Zurich 4-5 Sept

BiotechX Europe, Basel, 6-8 Oct

Biotech in Europe Forum, Basel, 8-9 Oct

German Stem Cell Network meeting, Munich 15-17 Oct

Orphan Drug Congress Europe, Amsterdam, 28-29 Oct

BioEurope, Vienna, 3-5 Nov

BioFit, Strasbourg, 2-3 Dec

L’article Meet us at Conferences and Partnerings est apparu en premier sur Ksilink.

]]> New publication on phenotypic and transcriptomic characterization, and machine learning-based classification of desmin-related cardiomyopathy disease features https://ksilink.com/new-publication-on-phenotypic-and-transcriptomic-characterization-and-machine-learning-based-classification-of-desmin-related-cardiomyopathy-disease-features/ Tue, 02 Sep 2025 14:23:02 +0000 https://ksilink.com/?p=7403 In collaboration with the Sorbonne University, Ksilink used both patient-derived and genome edited cellular models for desmin-related cardiomyopathy to analyze how the DESE439K mutation disrupts cellular function and contributes to disease phenotypes. Our findings highlighted key phenotypic defects such as cytoplasmic protein aggregation, mitochondrial and sarcomere defects, and contractile dysfunctions. We also developed a machine […]

L’article New publication on phenotypic and transcriptomic characterization, and machine learning-based classification of desmin-related cardiomyopathy disease features est apparu en premier sur Ksilink.

]]> In collaboration with the Sorbonne University, Ksilink used both patient-derived and genome edited cellular models for desmin-related cardiomyopathy to analyze how the DESE439K mutation disrupts cellular function and contributes to disease phenotypes. Our findings highlighted key phenotypic defects such as cytoplasmic protein aggregation, mitochondrial and sarcomere defects, and contractile dysfunctions. We also developed a machine learning prediction model to classify cellular phenotypes, which can be used for drug candidate screening.

Read the full article

L’article New publication on phenotypic and transcriptomic characterization, and machine learning-based classification of desmin-related cardiomyopathy disease features est apparu en premier sur Ksilink.

]]> New publication on morphological map of under- and overexpression of genes in human cells https://ksilink.com/new-publication-on-morphological-map-of-under-and-overexpression-of-genes-in-human-cells/ Tue, 02 Sep 2025 14:17:26 +0000 https://ksilink.com/?p=7401 As a member of the JUMP Cell Painting Consortium, Ksilink contributed to the perturbation of roughly 75% of the protein-coding genome in human U-2 OS cells, generating a rich resource of single-cell images and extracted features. These profiles capture the phenotypic impacts of perturbing 15,243 human genes, including overexpressing 12,609  and knocking out 7,975 genes. […]

L’article New publication on morphological map of under- and overexpression of genes in human cells est apparu en premier sur Ksilink.

]]> As a member of the JUMP Cell Painting Consortium, Ksilink contributed to the perturbation of roughly 75% of the protein-coding genome in human U-2 OS cells, generating a rich resource of single-cell images and extracted features. These profiles capture the phenotypic impacts of perturbing 15,243 human genes, including overexpressing 12,609  and knocking out 7,975 genes. Analysis of phenotypic profiles revealed previously undiscovered gene clusters and functional relationships, including those associated with mitochondrial function, cancer and neural processes.

Read the full article

L’article New publication on morphological map of under- and overexpression of genes in human cells est apparu en premier sur Ksilink.

]]> New publication on morphological profiling revealing neuroprotection in human dopaminergic neurons https://ksilink.com/new-publication-on-morphological-profiling-revealing-neuroprotection-via-mitochondrial-uncoupling-in-human-dopaminergic-neurons/ Fri, 29 Aug 2025 11:55:40 +0000 https://ksilink.com/?p=7370 In collaboration with the University of Luxembourg, Ksilink used a patient-derived cellular model for Parkinson’s Disease based on SNCA triplication and isogenic control mDA neurons to identify and rescue multiple phenotypes. Our pilot screen of > 1000 compounds revealed several compounds restoring healthy phenotypes, increasing Tyrosine hydroxylase (TH) and decreasing α-synuclein (αSyn) levels. Several hits […]

L’article New publication on morphological profiling revealing neuroprotection in human dopaminergic neurons est apparu en premier sur Ksilink.

]]> In collaboration with the University of Luxembourg, Ksilink used a patient-derived cellular model for Parkinson’s Disease based on SNCA triplication and isogenic control mDA neurons to identify and rescue multiple phenotypes. Our pilot screen of > 1000 compounds revealed several compounds restoring healthy phenotypes, increasing Tyrosine hydroxylase (TH) and decreasing α-synuclein (αSyn) levels. Several hits were linked to mitochondrial biology. 

Read the full article

L’article New publication on morphological profiling revealing neuroprotection in human dopaminergic neurons est apparu en premier sur Ksilink.

]]> We are thrilled to announce the arrival of our new Chief Operating Officer! https://ksilink.com/we-are-thrilled-to-announce-the-arrival-of-our-new-chief-operating-officer/ https://ksilink.com/we-are-thrilled-to-announce-the-arrival-of-our-new-chief-operating-officer/#respond Thu, 13 Feb 2025 12:20:38 +0000 https://www.ksilink.com/?p=6390 L’article We are thrilled to announce the arrival of our new Chief Operating Officer! est apparu en premier sur Ksilink.

]]>

Dr Helmut Haning has recently joined the management of Ksilink as COO, complementing the team with a longstanding experience in pharmaceutical drug discovery. He brings to the company a wealth of knowledge and expertise in drug discovery, strategy and operational excellence that will benefit in its future path.
Helmut is also Operating Partner at ARCHIMED, the world leading healthcare Private Equity fund.
In addition, he serves as SVP, Head of Drug Discovery for Metabiopharma in the field of rare genetic and autoimmune diseases.
Helmut started his career as an organic chemist. He joined Bayer, a German pharmaceutical company, in 1995 and subsequently assumed different roles of growing impact and responsibility in the company, retiring as Global Head of Medicinal Chemistry. He is the inventor of a marketed drug and several clinical candidates in different indications. He also build built an early partnering function covering all academic cooperations and early licensing activities. With Metabiopharma, he was successful in identifying a preclinical candidate for a rare genetic disease.

L’article We are thrilled to announce the arrival of our new Chief Operating Officer! est apparu en premier sur Ksilink.

]]> https://ksilink.com/we-are-thrilled-to-announce-the-arrival-of-our-new-chief-operating-officer/feed/ 0 Join Ksilink at BIO Partnering @ JPM Week 2025! https://ksilink.com/bio-partnering-jpm-week-2025/ https://ksilink.com/bio-partnering-jpm-week-2025/#respond Thu, 02 Jan 2025 10:13:52 +0000 https://www.ksilink.com/?p=6374 We are excited to announce that Mona Boyé, Head of BD & Partnerships, and Johannes Wilbertz, Team Leader Neuroscience, will be attending BIO Partnering @ JPM Week in San Francisco from January 13-16, 2025. This event is a leading gathering for the biotechnology industry, offering unparalleled opportunities for networking, partnering, and advancing business development goals. […]

L’article Join Ksilink at BIO Partnering @ JPM Week 2025! est apparu en premier sur Ksilink.

]]> We are excited to announce that Mona Boyé, Head of BD & Partnerships, and Johannes Wilbertz, Team Leader Neuroscience, will be attending BIO Partnering @ JPM Week in San Francisco from January 13-16, 2025. This event is a leading gathering for the biotechnology industry, offering unparalleled opportunities for networking, partnering, and advancing business development goals.

About Ksilink: Ksilink is at the forefront of patient-based drug discovery, designing and applying unique cellular assays for large-scale phenotypic screening. Our proprietary drug discovery engine, powered by AI-driven image analysis, aims to generate the most efficient first-in-class therapeutic molecules for next-generation medicine leveraging our extensive network of academic and clinical partners across Europe.

We look forward to connecting with you in San Francisco to explore new opportunities and collaborations!

L’article Join Ksilink at BIO Partnering @ JPM Week 2025! est apparu en premier sur Ksilink.

]]> https://ksilink.com/bio-partnering-jpm-week-2025/feed/ 0 Ksilink Advances PMDS Research and Disease Modelling https://ksilink.com/ksilink-advances-pmds-research-and-disease-modelling/ https://ksilink.com/ksilink-advances-pmds-research-and-disease-modelling/#respond Tue, 11 Jun 2024 08:05:25 +0000 https://www.ksilink.com/?p=5838 Strasbourg, France – Ksilink, together with our collaborators from I-Stem (Paris), has recently published a scientific paper that provides significant insights into Phelan-McDermid syndrome (PMDS), a genetic disorder that presents complex challenges in neurodevelopment and synaptic function. The research focuses on the SHANK3 gene, which is crucial for the proper development of neural connections. SHANK3 […]

L’article Ksilink Advances PMDS Research and Disease Modelling est apparu en premier sur Ksilink.

]]> Strasbourg, France – Ksilink, together with our collaborators from I-Stem (Paris), has recently published a scientific paper that provides significant insights into Phelan-McDermid syndrome (PMDS), a genetic disorder that presents complex challenges in neurodevelopment and synaptic function.

The research focuses on the SHANK3 gene, which is crucial for the proper development of neural connections. SHANK3 deficiency is a common factor in PMDS, leading to a range of developmental abnormalities. Our study detailed the developmental and synaptic disruptions caused by SHANK3 mutations and used a chemical genomics approach to identify potentially causative cellular pathways.

A key aspect of the research is the identification of small molecular compounds that can address the hyperdifferentiation phenotype seen in SHANK3 deficiency. Among these, one molecule has been highlighted for its ability to positively influence synapse formation and correct neurodevelopmental pathways potentially via influencing cellular actine dynamics.

Ksilink researchers will continue to explore the cellular biology of SHANK3-deficient cells. The identified compounds together with the used cell lines provide a model for understanding the effects of SHANK3 deficiency and hold potential for future development into therapeutic interventions.

Ksilink remains dedicated to advancing the understanding of PMDS and contributing to the broader field of drug discovery. Through continued research and collaboration, we aim to provide valuable models and tools that can aid in the development of effective treatments for PMDS and related disorders.

Our scientific paper can be accessed here: https://rdcu.be/dKnYt

For further details on our research, please visit our website or reach out to us.

L’article Ksilink Advances PMDS Research and Disease Modelling est apparu en premier sur Ksilink.

]]> https://ksilink.com/ksilink-advances-pmds-research-and-disease-modelling/feed/ 0 Artificial Intelligence in Mental Health Summit, July 1st and 2nd, Berlin https://ksilink.com/ai-summit-mental-health-berlin-2024/ https://ksilink.com/ai-summit-mental-health-berlin-2024/#respond Thu, 23 May 2024 14:22:31 +0000 https://www.ksilink.com/?p=5809 Join us for a two-day free event examining the role played by artificial intelligence and digital tools in understanding and supporting mental health. Hosted by the environMENTAL EU Project, Deutsches Zentrum für Psychische Gesundheit (DZPG) and EBRAINS, this event brings together experts within the field of mental health research, practice and policy. More information can […]

L’article Artificial Intelligence in Mental Health Summit, July 1st and 2nd, Berlin est apparu en premier sur Ksilink.

]]> Join us for a two-day free event examining the role played by artificial intelligence and digital tools in understanding and supporting mental health. Hosted by the environMENTAL EU Project, Deutsches Zentrum für Psychische Gesundheit (DZPG) and EBRAINS, this event brings together experts within the field of mental health research, practice and policy.

More information can be found ‘here‘

L’article Artificial Intelligence in Mental Health Summit, July 1st and 2nd, Berlin est apparu en premier sur Ksilink.

]]> https://ksilink.com/ai-summit-mental-health-berlin-2024/feed/ 0 02.04.2024: World Autism Awareness Day https://ksilink.com/world-autism-day/ https://ksilink.com/world-autism-day/#respond Tue, 02 Apr 2024 13:39:57 +0000 https://www.ksilink.com/?p=5741 Link to photo source (UN) At Ksilink, it is one of our core missions to develop new therapeutic modalities to treat autism and particularly a rare form called Phelan McDermid Syndrome (PMDS). In line with the principle of the 3R, we developed a relevant human stem cell-derived neuronal model that recapitulates disease features with our […]

L’article 02.04.2024: World Autism Awareness Day est apparu en premier sur Ksilink.

]]> Link to photo source (UN)

At Ksilink, it is one of our core missions to develop new therapeutic modalities to treat autism and particularly a rare form called Phelan McDermid Syndrome (PMDS). In line with the principle of the 3R, we developed a relevant human stem cell-derived neuronal model that recapitulates disease features with our collaborators at I-Stem (Establishment of heterozygous and homozygous SHANK3 knockout clonal pluripotent stem cells from the parental hESC line SA001 using CRISPR/Cas9 – ScienceDirect; Pharmacological modulation of developmental and synaptic phenotypes in human SHANK3 deficient stem cell-derived neuronal models | bioRxiv).

The deficit in SHANK3 protein (haploinsufficiency) which is a master scaffolding protein found in the postsynaptic density of excitatory synapses, is recognized as one of the major causes for different forms of autism including PMDS. Our current goal is to normalize the SHANK3 protein levels to physiological levels.
If you want to know more about us and our journey to treat PMDS, please contact us: contact@ksilink.com.

 

L’article 02.04.2024: World Autism Awareness Day est apparu en premier sur Ksilink.

]]> https://ksilink.com/world-autism-day/feed/ 0 New Study on the Impact of Endocrine Disrupting Chemicals on Parkinson’s Disease https://ksilink.com/new-study-on-the-impact-of-endocrine-disrupting-chemicals-on-parkinsons-disease/ https://ksilink.com/new-study-on-the-impact-of-endocrine-disrupting-chemicals-on-parkinsons-disease/#respond Mon, 11 Dec 2023 15:26:14 +0000 https://www.ksilink.com/?p=5518 New Study on the Impact of Endocrine Disrupting Chemicals on Parkinson’s Disease Ksilink, in collaboration with researchers from the University of Chieti in Italy, has published a new study on the effects of Endocrine Disrupting Chemicals (EDCs) on human stem cell-derived neurons. The research focused on bisphenols (BPs) and perfluoroalkyls (PFs), chemicals found in plastics […]

L’article New Study on the Impact of Endocrine Disrupting Chemicals on Parkinson’s Disease est apparu en premier sur Ksilink.

]]> New Study on the Impact of Endocrine Disrupting Chemicals on Parkinson’s Disease

Ksilink, in collaboration with researchers from the University of Chieti in Italy, has published a new study on the effects of Endocrine Disrupting Chemicals (EDCs) on human stem cell-derived neurons.

The research focused on bisphenols (BPs) and perfluoroalkyls (PFs), chemicals found in plastics and household products. The team analyzed their effects on human stem cell-derived midbrain dopaminergic neurons (mDANs), a cell type affected in Parkinson’s Disease (PD).

Using machine learning (ML), the team classified EDC-treated versus control mDANs based on 126 different phenotypic features. The results showed that EDC-treated mDANs were identified with high accuracies (0.88–0.96), indicating that EDCs induce changes in these cells.

The study found that EDC exposure led to an increase in alpha-synuclein (αSyn) and tyrosine hydroxylase (TH) staining intensity within the neurons, and a decrease in microtubule-associated protein 2 (MAP2) neurite length and branching. These changes are characteristic of PD, suggesting that EDCs may play a role in the disease’s development.

This study shows that using human stem cells to create models of neurons, along with high-content imaging, can help to spot changes in these cells when they are exposed to different chemicals. This method could be very useful in the process of discovering and prioritizing new drug-like molecules or detecting unwanted effects early on.

Link to study: https://www.nature.com/articles/s41598-023-49364-y

L’article New Study on the Impact of Endocrine Disrupting Chemicals on Parkinson’s Disease est apparu en premier sur Ksilink.

]]> https://ksilink.com/new-study-on-the-impact-of-endocrine-disrupting-chemicals-on-parkinsons-disease/feed/ 0